University of Athens, Greece.
University of Patras, Greece.
Acta Biomed. 2021 Oct 6;92(S1):e2021115. doi: 10.23750/abm.v92iS1.11120.
Rituximab is a monoclonal antibody against the protein CD20. Various lymphomas as well as non-malignant immune disorders are treated with this antibody. Hypersensitivity reactions associated with the use of rituximab include urticaria, hypotension, chest tightness, vomiting, oxygen desaturation and bronchospasm. A very uncommon case of hypertensive crisis and pulmonary edema following rituximab-induced hypersensitivity reaction in an 80-year-old man receiving rituximab for non-Hodgkin lymphoma is reported. Anaphylaxis manifesting as coronary vasospasm following drug treatment, including rituximab, could be proved a serious condition in patients who need specific treatment. In these patients desensitization protocols seem to be mandatory.
利妥昔单抗是一种针对蛋白 CD20 的单克隆抗体。该抗体可用于治疗各种淋巴瘤和非恶性免疫性疾病。与利妥昔单抗使用相关的超敏反应包括荨麻疹、低血压、胸闷、呕吐、氧饱和度下降和支气管痉挛。本文报告了一例非常罕见的 80 岁男性非霍奇金淋巴瘤患者在接受利妥昔单抗治疗后发生利妥昔单抗诱导的超敏反应导致高血压危象和肺水肿的病例。药物治疗（包括利妥昔单抗）后表现为冠状动脉痉挛的过敏反应可能在需要特定治疗的患者中被证明是一种严重的疾病。在这些患者中，脱敏方案似乎是强制性的。
